TREATMENT WITH MANDIBULAR ADVANCEMENT DEVICES IN COMORBID INSOMNIA AND SLEEP APNEA

Many people with obstructive sleep apnea (OSA) also suffer from chronic insomnia — a combination called COMISA — which is harder to treat and carries greater risk for heart disease and metabolic problems than either condition alone. This study tested whether a mandibular advancement oral appliance (OAm), a custom mouthguard-like device that repositions the jaw to keep the airway open during sleep, could help patients with COMISA improve both their breathing and their sleep quality. Researchers compared outcomes in OSA-only and COMISA patients treated with OAm therapy, and also tracked a small group of COMISA patients using a titratable (adjustable) device. They measured sleep architecture via polysomnography, insomnia severity, and heart rate variability (HRV) — a sensitive marker of how well the autonomic nervous system is functioning. The good news: breathing during sleep improved substantially in both groups, and COMISA patients saw a dramatic drop in the time it took them to fall asleep (from roughly 64 minutes down to 23 minutes). However, COMISA patients ended up with a slightly higher residual breathing-disruption score than OSA-only patients after treatment, suggesting the comorbid insomnia adds a layer of complexity. HRV also improved, pointing toward better autonomic balance — less 'fight-or-flight' dominance and more 'rest-and-digest' activity — after treatment. The findings suggest OAm therapy is a clinically meaningful option for COMISA, though the dual nature of the condition means outcomes may not be as complete as in OSA alone.

• In Cohort 1, post-treatment apnea-hypopnea index (AHI) improved significantly in both groups, but COMISA patients retained a slightly higher residual AHI compared to OSA-only patients (6.4 ± 6.9 vs. 3.7 ± 3.2 events/hour; p = 0.04), indicating incomplete normalization when insomnia is comorbid.
• Sleep latency in COMISA patients (Cohort 1) fell sharply from 63.6 ± 46.0 minutes to 22.8 ± 20.8 minutes after OAm treatment (p = 0.001), suggesting meaningful subjective and objective insomnia relief.
• In Cohort 2 (titratable OAm, n = 12 COMISA patients), AHI dropped from 22.7 ± 12.7 to 4.0 ± 3.5 events/hour post-treatment (p < threshold reported), and HRV analyses using both fast Fourier transform and wavelet spectral methods indicated improved autonomic nervous system modulation, consistent with a shift toward parasympathetic predominance.

This was a retrospective multicentric case-control study organized into two cohorts. Cohort 1 comprised 35 OSA-only patients and 31 COMISA patients who underwent standard OAm therapy; Cohort 2 included 12 COMISA patients treated specifically with a titratable OAm device. Outcomes were assessed pre- and post-treatment using clinical evaluation, full polysomnography, insomnia severity measures, and HRV analysis via time-domain and frequency-domain methods (fast Fourier transform and wavelet spectral analysis). The retrospective multicentric design and variable follow-up duration are not fully specified in the available abstract, which limits precision in characterizing the treatment window.

The retrospective design prevents causal inference, and the relatively small cohort sizes — especially Cohort 2 (n = 12) — limit statistical power and generalizability. No randomized control arm or comparison with CPAP or cognitive behavioral therapy for insomnia (CBT-I) is reported, making it impossible to determine whether OAm is superior, equivalent, or inferior to other first-line COMISA treatments. The slightly elevated residual AHI in COMISA patients raises the question of whether adjunct CBT-I or combined therapy would close this gap — a prospective randomized trial with longer follow-up and a CBT-I arm would be the logical next step. Additionally, the full HRV dataset appears truncated in the available abstract, so the magnitude and clinical significance of autonomic improvements should be interpreted with caution pending full-text review.

This study extends [§93] (Impact of Periodontal Inflammation on Allostatic Load) by demonstrating that a non-pharmacological intervention targeting a sleep-related physiological burden can shift autonomic markers in a direction consistent with reduced allostatic load, reinforcing the broader corpus theme that chronic physiological stressors are modifiable. It parallels [§83] (Repeated whole-body cryostimulation and blood pressure reduction) in that both articles track HRV and cardiovascular autonomic outcomes as proxies for systemic stress biology following an intervention, albeit through mechanistically distinct pathways. The finding that COMISA patients show incomplete AHI resolution despite treatment also resonates with [§34] (Trauma Exposure, Emotion Regulation, and Vagally Mediated HRV), where autonomic dysregulation tied to a comorbid psychological or behavioral dimension resists normalization by single-modality interventions. Finally, the use of HRV frequency-domain analysis as a central outcome biomarker connects methodologically with [§82] (Distinct psychophysiological biomarkers in IBS-C), where multi-domain autonomic profiling is similarly used to stratify and evaluate intervention response in a stress-biology-adjacent condition.

• Repeated whole-body cryostimulation promotes a blood pressure reduction at rest in healthy adult men
  Both studies use HRV (time- and frequency-domain) as the primary autonomic outcome to evaluate a non-pharmacological physical intervention; comparing them reveals how different stressor-removal strategies converge on parasympathetic restoration.
• The Impacts of Trauma Exposure on Emotion Regulation and 2 Vagally Mediated Heart Rate Variability
  Both articles examine vagally mediated HRV as an index of autonomic dysregulation, but in populations where a comorbid psychological/behavioral dimension (trauma vs. insomnia) complicates recovery — useful for understanding why single-modality treatment may leave residual autonomic burden.
• Distinct psychophysiological biomarkers and risk stratification models for irritable bowel syndrome with constipation (IBS-C) and diarrhea (IBS-D)
  Both studies deploy multi-domain HRV biomarker profiling (FFT and additional spectral methods) to evaluate intervention response in conditions at the intersection of sleep, stress, and autonomic biology, making them methodologically comparable.
• Impact of Periodontal Inflammation on Allostatic Load
  Both articles situate their intervention outcomes within the allostatic load framework; comparing them illustrates how different chronic physiological stressors (periodontal inflammation vs. sleep-disordered breathing with insomnia) converge on similar autonomic and cardiometabolic risk pathways.
• The Effect of Physiotherapy Integrated With Yoga and Mindfulness on Individuals With Fibromyalgia
  Both studies assess non-pharmacological interventions (OAm vs. physiotherapy with yoga/mindfulness) on autonomic and sleep-related outcomes in patients with chronic comorbid conditions, offering a cross-modal comparison of how different stress-reduction strategies affect HRV and subjective symptom burden.